Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Luckner Ulysse"'
Autor:
Bingidimi I. Mobele, Luckner Ulysse, Sripathy Venkatraman, Lawrence Lawless, Xuechuan Hong, Andrew Locke, Ravi Shanker Garigipati, Shengquan Duan, Kenneth He Huang, Alex Smith
Publikováno v:
Organic Process Research & Development. 16:1787-1793
A scalable process for the manufacture of a Hsp90 inhibitor was developed and optimized. Key features in the seven-step process include a selective SNAr reaction followed by an Ullmann-type coupling of indazolone to an aryl halide. This improved proc
Autor:
Kerry Spear, Sripathy Venkatraman, Bingidimi I. Mobele, Cameron Gibb, Brian E. Marron, Grant Andrew Mcnaughton-Smith, Stephen M. Shaw, Mark J. Suto, Luckner Ulysse, Carl A. Lindmark
Publikováno v:
Organic Process Research & Development. 16:1385-1392
A scalable process for the manufacture of a potassium ion channel blocker was developed and optimized. Key features of the process include an optimized Grignard reaction, a direct cyanation of the intermediate trityl alcohol derivative, and an improv
Autor:
Mark D. McLaws, Qiang Yang, Congxiang Zha, Brian P. Haney, Peter R. Guzzo, Liu Shuang, Daniel K. Keefe, Luckner Ulysse
Publikováno v:
Organic Process Research & Development. 16:499-506
Early process development toward a triple reuptake inhibitor is described. Three different routes were evaluated; one of them was optimized and scaled up to generate 470 g of API as this route minimized the formation of undesired side products. The s
Publikováno v:
Organic Process Research & Development. 14:225-228
Tetrahydroisoquinoline is a ubiquitous structural framework presented in numerous pharmacologically relevant molecules. Although accessible by the Pictet−Spengler cyclization, conditions commonly used for such cyclizations are often difficult to im
Autor:
Farahnaz Mohammadi, Bingidimi I. Mobele, Luckner Ulysse, Michael D. Ironside, Taryn Kinahan, Graham S. Knox, Steven V. Gagnier
Publikováno v:
Organic Process Research & Development. 10:914-920
(+)-Methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate hydrochloride (CTDP 31,446) is known as a dopamine reuptake inhibitor. This cocaine analogue lacking the tropane skeleton is being considered for potential treatment of cocaine addict